Last updated 2026-07-20
- Went public on NASDAQ (NVCR), Oct 2015
- Raised $100M debt round, Apr 2024
- Raised $150M debt round led by BioPharma Credit PLC, Jan 2018
Total raised
$252.0M
Last: Public Offering 2020-11
Stage
Public
Founded
2000
Headcount
1,605
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences
About
NovoCure is a global oncology company focused on extending survival in aggressive forms of cancer through its proprietary Tumor Treating Fields (TTFields) therapy. TTFields therapy uses low-intensity, intermediate-frequency alternating electric fields to disrupt cancer cell division. The company's commercialized products, including Optune Gio, Optune Lua, and Optune Pax, are approved in certain countries for the treatment of glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and locally advanced pancreatic cancer. NovoCure conducts research and development in Haifa, Israel, and has operations across North America, Europe, the Middle East, and Asia.
Funding history · 5 rounds · $252.0M total
2024-04
Debt Financing
$100.0M
2020-10
Follow-on PO
Undisclosed
2018-11
Grant
$2.0M
2018-01
Debt Financing
$150.0M
★ BioPharma Credit PLC
2015-09
Follow-on PO
Undisclosed
Headcount over time
From 368 (2017-08) to 1,485 (2026-03) · +1,117 (+304%) · 71 points · source: Finder history + radar grounding
Q&A
- What is Novocure's primary therapy for solid tumor cancers?
- Novocure develops and commercializes Tumor Treating Fields (TTFields) therapy, which uses low-intensity, intermediate-frequency alternating electric fields to disrupt cancer cell division.
- When did Novocure go public and on which exchange?
- Novocure went public on NASDAQ in October 2015, raising $165 million through its public offering.
- What was a key leadership change announced in September 2024?
- In September 2024, Novocure announced a planned CEO transition, with Asaf Danziger retiring and CFO Ashley Cordova named as his successor.
- What recent FDA approval did Novocure receive for its Optune Lua device?
- In October 2024, Novocure's Optune Lua received FDA approval for the treatment of metastatic non-small cell lung cancer.
- What was a significant development regarding Novocure's pancreatic cancer therapy in December 2024?
- In December 2024, Novocure announced positive topline results from its Phase 3 PANOVA-3 clinical trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer.
- What was a notable FDA approval for Novocure in February 2026?
- In February 2026, the U.S. FDA approved Novocure’s Optune Pax® for the treatment of locally advanced pancreatic cancer.
- What was the outcome of Novocure's Phase 3 TRIDENT trial for newly diagnosed glioblastoma in June 2026?
- In June 2026, Novocure announced that the Phase 3 TRIDENT trial evaluating earlier use of Tumor Treating Fields therapy in newly diagnosed glioblastoma did not meet its primary endpoint.
Team · 1
Yoram Palti
Founder · Founder, CTO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcarePatientsProviders
Business model
B2B
Highlights
1 Patents
Tags
cell-therapycancernon-invasivemedical-technologieschemotherapyoncologypharmaceuticalstreatmentswearable
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
Identifiers & details
| Legal name | NovoCure Limited |
|---|---|
| Founded | 2000 |
| Employees (exact) | 1605 |
| Offices | Mnchen; Saint Helier; New York; Malvern; Japan; Root; Portsmouth |
| Market cap | $1.4B |
| Status reason | Public on NASDAQ on Oct, 2015 |
| Wikidata QID | Q30267502 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2015-10 | NASDAQ | NVCR | $165.0M |
Radar intelligence
Patents
| EPO | 372 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
App Store
| App | Rating | Ratings |
|---|---|---|
| MyNovocure | 3.42857 |
Web history (Wayback)
| Domain | novocure.com |
|---|
Wikidata
| QID | Q30267502 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512768003 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 1999-04-15 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | חת נחום 5 טירת כרמל |